

## Financial Results for 2Q FY2010

November 19, 2010

Meiji Holdings Co., Ltd.





- 1. FY2010 Business Plan
- **2.** 1HFY2010: (Meiji Holdings) Outline of Consolidated Financial Results
- **3.** 1HFY2010: (Operating Companies) Outline of Consolidated Financial Results
- 4. FY2010: Outlook for Consolidated Financial Results
- 5. Closing



## 1. FY2010 Business Plan

## **1.** FY2010 Business Plan



# Expanding businesses and improving profitability

# Business environments are expected to be increasingly difficult

- Stagnant demand
- Increasing consumer demand for low-priced products
- •Raw material prices remaining at high levels
- Lowering of drug prices

### Maintain Medium-Term Business Plan

- •Strengthen existing businesses in our specialty fields
- •Create new demand be leveraging the knowledge and expertise of Group members

# Achieve targets in FY2010, as we did in FY2009

### FY2010 Business Plan

		FY2010 plan	FY2009 results
	Net Sales	1,131.0	1,106.6
Meiji Holdings	Operating Income	29.0	28.7
	Ordinary Income	29.0	28.3
	Net Sales	608.5	600.0
Dairy Products	Operating Income	14.7	13.4
Confectionary	Net Sales	302.0	293.0
and Healthcare	Operating Income	5.5	4.4
Dharmanautianta	Net Sales	131.2	127.6
Pharmaceuticals	Operating Income	7.1	8.4
Services and	Net Sales	144.9	140.8
Other	Operating Income	2.6	3.4

(billions of yen, eliminations not included)

\* Figures are unchanged from forecasts announced at Information Meeting on May 26.




## 2. 1HFY2010: (Meiji Holdings) Outline of Consolidated Financial Results

## (1) Consolidated Financial Results



	1HFY2010 (billions of yen)	YoY Change (billions of yen, %)				Change from (billions o	-
Net Sales	561.3	+6.0	+1.1	(3.1)	(0.6)		
Gross Profit	191.2	+8.1	+4.5		—		
SG&A	173.7	+4.2	+2.5	_	—		
Operating Income	17.5	+3.9	+29.3	+5.5	+46.2		
Non-operating Income/Loss	1.6	+1.7	—	Ι	—		
Ordinary Income	19.1	+5.7	+42.8	+7.1	+60.0		
Extraordinary Income/Loss	(1.7)	+0.1	—	_	—		
Tax Expenses, etc.	7.8	+1.9	+32.3	_	_		
Net Income	9.3	+3.9	+73.5	+3.6	+64.5		

6





### 1) Financial Results by Segment

	Net Sales			Ор	erating Inco	ome
	1HFY2010 (billions of yen)	YoY Change (%)	Change from initial plan (%)	1HFY2010 (billions of yen)	YoY Change (%)	Change from initial plan (%)
Dairy Products	319.1	+0.9	+0.0	10.0	(0.5)	+1.6
Confectionary and Healthcare	135.0	(1.4)	(3.5)	0.1	+35.8	(75.3)
Pharmaceuticals	61.1	+5.3	+2.6	5.2	+138.4	+768.8
Reporting Segments Total	515.3	+0.8	(0.6)	15.4	+24.3	+38.9
Other	74.9	+3.7	+0.9	2.2	+29.1	+145.0
Total	590.3	+1.2	(0.4)	17.6	+24.9	+46.9
Adjustments	(29.0)		_	(0.0)		—
Amount presented in income statement	561.3	+1.1	(0.6)	17.5	+29.3	+46.1





2) Results for Dairy Products

Net Sales				<b>Operating Income</b>	
1HFY2010	YoY Change (Amount)	Change from initial plan	1HFY2010	YoY Change (Amount)	Change from initial plan
319.1 billion yen	+0.9% (+2.9 billion yen)	+0.0%	10.0 billion yen	-0.5% (-0.0 billion yen)	+1.6%

Points of 1HF FY results

- Stagnant sales of drinking milk extraordinary (excluding "Meiji Oishii Gyunyu"), powdered milk, beverages and margarine
- Brisk sales of ice cream due to hot summer weather (increased by 15.1%)
- Expanded sales of cheese, nutritional products (enteral formula, "VAAM"), and other products
- (Significant increase in selling expenses) is larger than (decrease in the costs of procuring raw materials)

# (2) Segment Information



### 3) Results for Confectionary and Healthcare

Net Sales			Operating Income		
1HFY2010	YoY Change (Amount)	Change from initial plan	1HFY2010	YoY Change (Amount)	Change from initial plan
135.0 billion yen	-1.4% (-1.8 billion yen)	-3.5%	0.1 billion yen	+35.8% (+0.0 billion yen)	-75.3%

Points of 1HF FY results

- · Significant adverse impact of extraordinary hot summer weather
- Year-on-year market shrinkage in five mainstay categories of the confectionary business
- · Steady sales of chocolate, chewing gum, "Amino Collagen" and "Savas"
- Confectionary's profitability structure improvement and cost down activities (e.g. reduced selling expenses) brought more profit than 1HFY2009

# (2) Segment Information



### 4) Results for Pharmaceuticals

Net Sales				Operating Income	
1HFY2010	YoY Change (Amount)	Change from initial plan	1HFY2010	YoY Change (Amount)	Change from initial plan
61.1 billion yen	+5.3% (+3.0 billion yen)	+2.6%	5.2 billion yen	+138.4% (+3.0 billion yen)	+768.8%

Points of 1HF FY results

Achieved sales increase despite the impact of NHI price revisions (-2.9 billion yen)

- · Sales contribution of two new drug products, "REFLEX®" "ORAPENEM®"
- Expanded sales of the antibacterial drug "MEIACT" and generic drugs

Significant profit increase due to a sales increase and other factors

• Rise in marginal profit, improvement in the product mix, decreased R&D costs and selling expenses



#### 1) Consolidated Balance Sheets (billions of yen) Consolidated Consolidated 1HFY2010 Compared to YoY 1HFY2010 Compared to YoY beginning of beginning of Change Change period period **Current Assets** 311.5 +1.9+4.6Current Liabilities 301.7 +0.9(11.9) Cash and Deposits 14.3 Debts (trade) (2.3)(1.4)99.6 +4.4(1.0) Notes and Accounts Debts (finance) 153.5 (0.9) +1.1102.7 (3.1)(12.1)Receivable Inventories 112.8 +5.7Others +1.2 +1.599.3 (0.3) 30.7 +3.7Long-term Liabilities 128.1 Others (0.7)(3.3) +1.8 **Fixed Assets** 417.5 (2.9)(4.5)Debts (finance) 94.1 (2.8)+2.2 Tangible Assets 331.6 (1.1)(3.1)Others 34.0 (0.5)(0.3) **Total Liabilities** Intangible Assets 9.4 (1.0)(1.0)429.8 (2.4)(10.0)Shareholders' **Investments and Other** (0.7) (0.3)294.5 +5.2+13.276.3 Assets Equity Others 4.6 (3.8) (3.0) **Total Net Assets** 299.2 +1.4+10.1 **Total Assets Total Liabilities and** +0.0729.0 (0.9) +0.0729.0 (0.9)**Net Assets**

•The balance of interest-bearing debt includes

Balance of interest-bearing debt 197.2

(5.9)

(9.7)

discount bills.

11

## (3) Consolidated Financial Review



2) Statements of Changes in Net Assets	(billions of yen)
(April 1, 2010 — September 30, 2010)	Total Net Assets
Balance at March 31, 2010	297.7
Changes during the fiscal period	
Cash dividends	(5.8)
Net income	9.3
Acquisition of treasury stock	(0.0)
Disposal of treasury stock	+0.0
Change of scope of consolidation	1.8
Others	(3.8)
Total changes during the fiscal period	1.4
Balance at September 30, 2010	299.2

## (3) Consolidated Financial Review



### 3) Consolidated Financial Indices and Cash Flows

(billions of yen)

	1HFY2010 Sept. 30	FY2009 March 31	1HFY2009 Sept. 30
Earnings per Share (EPS)	127.26 yen	177.73 yen	73.42 yen
Return on Equity (ROE)	3.2%	4.6%	1.9%
Cash Flows from Operating Activities (I)	29.8	47.7	24.3
Cash Flows from Investing Activities (II)	(18.9)	(33.6)	(14.6)
Cash Flows from Financing Activities (III)	(12.5)	(12.6)	(8.7)
Cash and Cash Equivalents at the end of the term	14.2	16.0	15.7
Free Cash Flow ( (I) + (II) )	+10.9	+14.1	+9.7

## (3) Consolidated Financial Review



### 4) Projected Dividends

	Div	Payout ratio		
(Record date)	Interim	(Consolidated)		
Year ending March 2011	40.00 yen	40.00 yen	80.00 yen	39.3%

(Note) For the year ending March 2011, we plan dividend with the interim-end closing date as the record date ("interim dividend").

Shareholder Special Benefit Plan

Status of donation options \*

Donations via the shareholder special benefit plan

#### in FY2010

•Number of shareholders who agreed to donate: Approx. 1,500	
Corresponding amount donated by shareholders: Approx. 5  million yen	



People who received the donated items

Meiji Holdings donated confectionaries equivalent to 10 million yen (5 million yen from shareholders +5 million yen from Meiji Holdings) to158 schools for children with special needs nationwide.



## 5) Capital Expenditures, Depreciation, R&D Expenses (billions of yen)

	1HFY2010			Note	
	Results	(Meiji Seika)	(Meiji Dairies)	NOLE	
Capital Expenditures	17.5	8.0	9.5	Cash basis (FY2009, Approval basis: 63.8 billion yen)	
Depreciation	18.8	9.2	9.6	Property, plant and equipment Including leases	
R&D Expenses	10.6	7.1	3.5		

(Note) Capital expenditures, depreciation expenses and R&D expenses are presented in the combined figures of Meiji Seika and Meiji Dairies (consolidated basis).

#### \* Main Capital Expenditures

		Completion date	Total amount
Dairy Products	Construction of Kansai ice cream plant	From 1HFY2011 onward	9.2 billion yen
Confectionary and Healthcare	Construction of manufacturing building at Osaka Plant	March 2011 (planned)	5.0 billion yen
Pharmaceuticals	Manufacturing facilities at P.T. Meiji Indonesia	August 2010 onward	Approx. 4.0 billion yen



# 3. 1HFY2010: (Operating Companies) Outline of Consolidated Financial Results

(1) Meiji Seika

(2) Meiji Dairies

### 1) Income Summary

	1HFY2010 (billions of yen)	YoY Change (billions of yen)	YoY Change (%)
Net Sales	193.9	+3.5	+1.9
Gross Profit	80.0	+1.6	+2.1
SG&A	75.2	(1.7)	(2.2)
Operating Income	4.8	+3.4	+242.0
Ordinary Income	6.8	+5.4	+374.4
Net Income	3.0	+3.5	

## 2) Net Sales by Division

	1HFY2010 (billions of yen)	Change from 1HFY2009 (%)
Food & Healthcare	134.8	(1.4)
Confectionary	61.3	(4.3)
Healthcare	23.2	(5.1)
Institutional Food Products	40.1	+7.3
Overseas (Import and Export)	10.1	(5.7)
Pharmaceuticals	57.5	+10.4
Ethical Pharmaceuticals	48.9	+11.2
Agricultural Chemicals and Veterinary Drugs	8.5	+6.3
Others	1.5	(3.7)
Total	193.9	+1.9

## 3) Segment Information

(billions of yen)

	Fo	od & Healthc	are	Pharmaceuticals			
	1HFY2010	1HFY2009	YoY change	1HFY2010	1HFY2009	YoY change	
Net Sales	134.8	136.6	(1.8)	57.5	52.0	+5.4	
Operating Income	0.1	0.1	+0.0	4.8	1.5	+3.2	
	Others		Total				
	1HFY2010	1HFY2009	YoY change	1HFY2010	1HFY2009	YoY change	
Net Sales	1.5	1.5	(0.0)	193.9	190.3	+3.5	
Operating	0.2	0.4	(0.1)	5.2	2.1	+3.1	


(Notes) 1. Net sales are presented in figures after consolidation elimination for transactions within the Meiji Seika Group. Operating incomes are presented in figures before consolidation elimination for transactions within the Meiji Seika Group.

2. "Others" corresponds to the previous "Office Building Leasing and Others" segment.

19

4) Factors in Increase/Decrease of Operating Income

(billions of yen)



#### \* Operating incomes are presented in figures after elimination.

### 1) Income Summary

	1HFY2010 (billions of yen)	YoY Change (billions of yen)	YoY Change (%)
Net Sales	373.5	+4.3	+1.2
Gross Profit	111.1	+6.4	+6.2
SG&A	98.6	+6.0	+6.6
Operating Income	12.4	+0.3	+3.3
Ordinary Income	12.5	+0.4	+3.8
Net Income	6.5	+0.5	+9.4

### 2) Net Sales by Division

	1HFY2010 (billions of yen)	Change from 1HFY2009 (%)	Change in volume from 1HFY2009 (%)
Meiji Dairies Total (non- consolidated basis ) (1)	261.9	+1.5	
Fresh dairy	150.8	+0.3	_
(Drinking milk) (Note1) (Yogurt)	58.4 59.2	(1.8) +2.3	(0.9) +1.9
Processed milk products	39.4	(0.6)	_
(Powdered milk) (Butter) (Cheese)	16.9 7.3 14.4	(7.4) +1.8 +6.3	(4.2) +5.5 +16.5
lce cream	29.6	+15.1	+13.4
Beverages	12.3	(8.7)	(9.4)
Others (Note 2)	29.7	+3.7	_
Sales of consolidated subsidiaries (2)	185.3	(0.1)	—
Consolidation elimination (3)	(73.7)	(0.8)	_
Total (1)+(2)+(3)	373.5	+1.2	

(Notes) 1. Figures of drinking milk represent the total of milk, processed milk and milk beverages.

2. "Others" includes nutritional products, frozen food, margarine, etc.

(billions of yen)

### 3) Segment Information


	Food			Others			Total		
	1HFY2010	1HFY2009	YoY Change	1HFY2010	1HFY2009	YoY Change	1HFY2010	1HFY2009	YoY Change
Net Sales	319.1	316.1	+2.9	76.2	75.1	+1.1	395.3	391.2	+4.1
Operating Income	10.0	10.1	(0.0)	2.3	1.9	+0.4	12.3	12.0	+0.3

(Notes) 1. The above figures are presented in figures before consolidation elimination for transactions within the Meiji Dairies Group.

2. "Others" corresponds to the previous "Services and other" segment.

4) Factors in Increase/Decrease of Operating Income

(billions of yen)



#### \* Operating incomes are presented in figures after elimination.



## 4. FY2010: Outlook for Consolidated Financial Results



1

Results

2H Plan

FY2010 Plan

26



(1) (Meiji Holdings) **Outlook for Consolidated Financial Results** 

(billions of yen)								
	Net Sales	Operating Income	Ordinary Income	Net Income				
Results	561.3	17.5	19.1	9.3				
Compared to initial plan	(3.1)	+5.5	+7.1	+3.6				
YoY change	+6.0	+3.9	+5.7	+3.9				
Revised plan	558.6	11.9	10.8	5.6				
Compared to initial plan	(7.8)	(5.0)	(6.1)	(3.6)				
YoY change	+7.3	(3.2)	(4.0)	(2.0)				
Revised plan	1,120.0	29.5	30.0	15.0				
Compared to initial plan	(11.0)	+0.5	+1.0					
YoY change	+13.3	+0.7	+1.6	+1.9				

## (2) (Operating Companies)

**Outlook for Consolidated Financial Results** 




Operating Ordinary **Net Sales Net Income** Income Incomé Results 193.9 4.8 6.8 3.0 Results Ì Compared to (4.0) +4.3+6.3+3.5initial plan Meiji Seika 5.6 233.0 6.6 2.9 **Revised** plan 2H Plan Compared to (5.3)(3.5)+1.0(4.3)initial plan 427.0 11.5 12.5 6.0 **Revised** plan П =Y2010 Plan **Compared to** (3.0)+1.0initial plan +1.2+15.9+0.6+1.4**YoY change** Results 373.5 12.4 12.5 6.5 Results Ì **Compared to** +2.0+0.9+1.0+0.3initial plan Meiji Dairies 329.4 5.6 4.9 2.4 **Revised plan** 2H Plan **Compared to** (10.0)(1.0)(0.3)(0.4)initial plan 703.0 18.0 17.5 9.0 **Revised plan** FY201 Plan **Compared to** +0.5(7.9) \_\_\_\_ initial plan 0 +0.4+0.2+0.6**YoY change** (1.4)

## (3) (Meiji Seika) Factors in Increase/Decrease of Operating Income



### 1) Revised Plan for 2HFY2010




#### \*Operating incomes are presented in the figures after elimination.

(billions of yen)

## (3) (Meiji Seika) Factors in Increase/Decrease of Operating Income



### 2) Revised Full-Year Plan




#### \*Operating incomes are presented in the figures after elimination.

## (4) (Meiji Dairies) Factors in Increase/Decrease of Operating Income

### 1) Revised Plan for 2HFY2010

(billions of yen)

mei




### \*Operating incomes are presented in the figures after elimination.

## (4) (Meiji Dairies) Factors in Increase/Decrease of Operating Income



### 2) Revised Full-Year Plan

(billions of yen)



#### \*Operating incomes are presented in the figures after elimination.



### 1) Net Sales and Operating Income by Segment

### (Net Sales)

(billions of yen)

		Total	Dairy Products	Confectionary and Healthcare	Pharma- ceuticals	Other	Adjustments
2HFY2010	Revised plan	558.6	278.8	164.9	69.1	72.0	(26.2)
	Change from initial plan	(7.8)	(10.5)	+2.9	(2.4)	+1.4	+0.8
	Revised plan	1,120.0	598.0	300.0	130.3	147.0	(55.3)
FY2010	Change from initial plan	(11.0)	(10.5)	(2.0)	(0.9)	+2.1	+0.3

### (Operating Income)

#### (billions of yen)

		Total	Dairy Products	Confectionary and Healthcare	Pharma- ceuticals	Other	Adjustments
2HFY2010	Revised plan	11.9	4.3	5.3	1.8	1.0	(0.7)
	Change from initial plan	(5.0)	(0.4)	+0.4	(4.6)	(0.6)	+0.1
	Revised plan	29.5	14.4	5.5	7.1	3.3	(0.8)
FY2010	Change from initial plan	+0.5	(0.3)	_	_	+0.7	+0.1



### 2) Dairy Products

#### (billions of yen)

	Net Sales	Change from initial plan (Amount, %)	YoY Change (Amount, %)	Operating Income	Change from initial plan (Amount)	YoY Change (Amount)	
2H Revised	278.8	(10.5)	(5.0)	4.3	(0.4)	+1.0	
plan		(3.6%)	(1.8%)	4.5	(0.4)	T1.0	
Full-year	509.0	(10.5)	(2.0)	4 4 4	(0.2)	. 0 0	
Revised plan	598.0	(1.7%)	(0.3%)	14.4	(0.3)	+0.9	

**Risk Factors and Issues** 

Low price competition in ongoing deflation

### Points

- Securing sales by developing products that utilize superiority and differentiation
- Restricting cost increases by effectively spending sales promotion expenses



2) Dairy Products

### Sales Targets for Our Leading Products

(billions of yen)

	2HFY201	0 Outlook	Full-Year (	Full-Year Outlook		FY2010 Initial plan	
		YoY Change (%)		YoY Change (%)		YoY Change (%)	
Meiji Oishii Gyunyu	23.6	+0.4	50.4	+1.6	49.6	+0.1	
Meiji Bulgaria Yogurt	30.8	+0.4	66.0	(0.7)	67.2	+1.1	
Meiji Probio Yogurt LG21	17.3	+0.6	35.0	(0.4)	34.1	(2.9)	
Home delivery items	21.5	+0.3	43.4	+0.1	44.5	+2.7	
Meiji Hokkaido Tokachi Cheese	5.7	+2.0	11.1	+1.9	11.1	+1.4	
Meiji Essel Super Cup	6.3	+1.0	18.1	+5.9	17.5	+2.6	
VAAM	3.1	+3.6	8.0	+4.9	8.0	+5.9	



2) Dairy Products


Enhancing sales of "Meiji Oishii Gyunyu"

 Appealing to customers through consumer campaigns and communication at retail stores

Enhancing sales of yogurt

- Emphasizing the functionality of "Meiji Bulgaria Yogurt," "Meiji Probio Yogurt LG21" and "Meiji Yogurt R-1"
- Launching "meiji Yoplait" nationwide (from October)
  Expanding the delivery business through specialized products
- New products: "Meiji Milk de Genki" and "Meiji Uruou Collagen"
- "Meiji Keikai Glucosamine"

35




### "Meiji Oishii Gyunyu" series



Enhancing sales by emphasizing functionality



(New products, for delivery only)



36

Expanding sales of "Meiji Hokkaido Tokachi Cheese"

 Continuing to implement advertising and consume campaigns, especially for "Meiji Hokkaido Tokachi Smart Cheese"

Enhancing the product lineup of ice cream

- Launching limited-time-only products of the "Meiji Essel Super Cup" series
- Increasing the products which feature Meiji Seika's confectionary products brand

Expanding the sales channels for enteral formula

 Expanding sales to hospitals, particularly for "enteral formula varieties for specific pathological condition"



"Meiji Hokkaido Tokachi Smart Cheese"






"Meiji ALMOND Chocolate Ice Bar"

"Meiji Essel Super Cup Ultra Vanilla"



Meiji Mei Balance series (enteral formula)







### 3) Confectionary and Healthcare

(billions of yen)

	Net Sales	Change from initial plan (Amount, %)	YoY Change (Amount, %)	Operating Income	Change from initial plan (Amount)	YoY Change (Amount)
2H Revised plan	164.9	+2.9 +1.8%	+8.7 +5.6%	5.3	+0.4	+1.0
Full-year		(2.0)	+5.6%	5.5		+1.0
Revised plan		(0.7%)	+2.4%			

### **Risk Factors and Issues**

- Continuously weak confectionary market
- Prices of major raw materials for confectionaries surging, remaining at high levels (e.g. cacao beans, sugar)

### Points

- Expanding sales of chocolate during peak demand periods for confectionaries by taking advantage of brand power (Maximizing the product exposure of "Meiji Milk Chocolate" and expanding sales of the winter-only "Meltykiss series")
- · Concentrating in mainstay brands of the healthcare segment to expand their sales
- Securing profits through the promotion of cost reductions, including improvement in profit structure of the confectionary business



### 3) Confectionary and Healthcare

Confectionary: expanding sales during high season



Enhancing product lineup of chocolate bars Extending the "Meltykiss" brand in other brands

(Demand for hand-made chocolate: Christmas/Valentine's Day/White Day)

 Developing "Meltykiss" into a mega-brand (New-concept products, combinations with "Fran" and "Meiji ALMOND chocolate")

### Chewing gum

- Expanding the product exposure of "Xylish" by introducing new flavors
- Establishing the new brands of "MINTZ" and "Sweets Gum" in the market



Package renewal: "MINTZ"

Introducing new flavors for "Xylish" gum



### 3) Confectionary and Healthcare

Healthcare: concentrating in mainstay brands

- "Savas" (Protein for athletes)
- Enhancing sales along with the expansion of the market for joggers
- Increasing the hosting of seminars as part of promotional activities
- "Amino Collagen"
- Expanding targets by enhancing product lineup
- "ISODINE®"
- Enhancing sales promotion in retail stores for periods of high demand (gargling and hand wash)
- Expanding the product exposure of "Foam Hand Wash" for its
  - second year and establishing the brand in the market



### "Savas Runner Protein"

速度型高吸収 コラークン配合	meiji Anico Collasen PSJ 27-772 20-77	meiji PREMIUM 72724 PEIDO PEID
Younger	Enhancing the	Eleder
generation	product lineup	generation
riods of high		
Mach" for ita		

"ISODINE® Foam Hand Wash"



### 4) Pharmaceuticals

### (billions of yen)

	Net Sales	Change from initial plan (Amount, %)	YoY Change (Amount, %)	Operating Income	Change from initial plan (Amount)	YoY Change (Amount)
2H Revised plan	69.1	(2.4)	(0.4) (0.6%)	1.8	(4.6)	(4.4)
Full-year Revised plan	130.3	(0.9)	+2.6	7.1		(1.3)
		(0.7%)	+2.1%			

### **Risk Factors and Issues**

• Impact of NHI price revision (-2.9 billion yen in the first half, -3.1 billion yen in the second half, -6.0 billion yen for

the full-year)

### Points

- Increasing sales amounts, particularly for the mainstay product "MEIACT" (offsetting the impact of drug price revisions)
- · Enhancing sales activities for two new drug products, "REFLEX®" and "ORAPENEM®"
- Expanding sales of generic drugs (full-year: 18 billion yen, achieving the target of the medium-term business plan one year in advance)



### 4) Pharmaceuticals

Establishing new drugs in the market and expanding sales of generic drugs

Enhancing product lineup in strategic therapeutic areas "REFLEX®"

 Encouraging the use of pharmaceuticals by emphasizing their distinctive features

Continuing to expand sales of generic drugs

 Leveraging the trust in the "Meiji brand" and our strengths in drug manufacturing technology, quality, stable production, and Information provision

"MEIACT"

 Continuing to enlarge our market share by increasing sales, despite the shrinking of the market



Antidepressant drug "REFLEX®"



Calcium channel blocker "AMLODIPINE"



The Chemical Compar

4) Pharmaceuticals

Agricultural chemicals, veterinary drugs

Promoting the registration and approval of new products

- "ZAXA" liquid-formula
- "MARBOCYL" injectable drug (launched in October 2010)

Promoting the development of an operational structure for overseas business expansion

Promoting R&D to strengthen business foundation

Expediting the development of products developed in-house Reinforcing product portfolio and promoting alliances



(Horticultural insecticide)

•Licensed out to BASF SE

(based in Germany) in May 2010

• Preparing to make application in Japan



# 5. Closing — Toward a New Corporate Reorganization —

(1) Global Strategy

(2) Fusion of Technologies



1) Meiji Group "2020 Vision" – Actively Expanding Our International Food Business

The Meiji Group aims to become a corporate group that brightens customers' daily lives not only in Japan but also in overseas markets through a broad business portfolio.

(Strategies)

- Develop the business into a core business of the Meiji Group through prioritized resource allocation
- Raise the profile of the " meiji " brand in overseas markets as a trusted brand
- Conduct prioritized management of the business by focusing on three main geographic areas (China, Southeast Asia, and the U.S.)
- Expand this business, including through alliances and M&As

	China		Southeast Asia		U.S.
Businesses to be strengthened	Confectionaries	Ice cream Healthcare products	Confectionaries	Dairy products Healthcare products	Confectionaries
Businesses to be newly-launched for 2020 Vision	Dairy products		Ice cream		Healthcare products


### Target net sales for FY2020: ¥150 billion

(Results for FY2009: Approximately ¥50 billion, calculated simply by combining available figures.)



2) Meiji Group "2020 Vision" – Actively Expanding the International Pharmaceuticals Business

Brightening the daily lives of the people worldwide by strengthening business operations in growing markets in Asia and other emerging economies.



45

#### (Strategies)

- Enhance the presence of overseas group companies (in China, Thailand, Indonesia, and Spain); build and strengthen relationships with local partners
- Establish a structure for high-quality products, stable supply, and low-cost operations by optimizing production systems and improving their efficiency
- Develop business in the market of affordably priced drugs, mainly in Asia and emerging countries
  - Proactively launch antibacterial drugs, generic drugs, and agricultural chemicals
  - Establish value chains ranging from the manufacturing of drug ingredients to the in-house sales network
- Develop business by forming alliances (including M&As) in Asia, Europe, or the U.S.
- Utilize local human resources and develop global human resources

### Target net sales for FY2020: ¥200 billion



### 3) Overseas Bases: Dairy Products



Guangdong M&F-Yantang Dairy Products Co., Ltd.



CP-Meiji Co., Ltd. (Thailand)

46



Guangdong M&F-Yantang Dairy Products : Ice cream



CP-Meiji's products line-up



CP-Meiji products in supermarket



4) Overseas Bases: Confectionary and Healthcare





Meiji Seika Food Industry (Shanghai) Co., Ltd.



Meiji Seika (Shanghai)' s products line-up

Meiji Seika (Shanghai) Co., Ltd.



D.F. Stauffer Biscuit Co., Inc. (U.S.)

47



Meiji Seika (Singapore) Pte. Ltd.



Convenience store in Shanghai district



### 5) Overseas Bases: Pharmaceuticals



Meiji Lukang Pharmaceutical Co., Ltd.



Shantou Meiji Pharmaceuticals Co., Ltd.





"MEIACT" (Sold overseas)



P.T. Meiji Indonesian Pharmaceutical Industries

48



Tedec-Meiji Farma, S.A. (Spain)




Thai Meiji Pharmaceuticals Co., Ltd.

# (2) Fusion of Technologies



1) Expansion of market coverage by management integration—Enhancement of distribution

and corporate image—




# (2) Fusion of Technologies



2) Expansion of market coverage by management integration—Expansion of eating





Possibility of developing markets (e.g. utilizing dairy products to develop confectionaries that can be eaten at work)



The familiarity of our dairy products with the younger generation and that of our confectionary products with the middle-aged and older generations will further increase.

# (2) Fusion of Technologies



3) Expansion of market coverage by management integration—Summary—

Factors to expand market coverage by management integration

- 1. Expansion of distribution
- 2. Expansion of our image in the consumer's mind
- 3. Expansion of eating occasions
- 4. Expansion of consumer demographics

Meiji Dairies and Meiji Seika own core manufacturing technologies to capitalize on the potential for expanding these markets.

The core manufacturing technologies must be integrated to strengthen product competitiveness and create new products.

## meiji

- The forward-looking statements described in this material, such as business forecasts, are based on information available at the time of the release of this presentation and reasonable assumptions made by the Company. Actual results could differ materially from forecasts due to various factors.
- Although this material includes information concerning pharmaceutical products (including those currently under development), such descriptions are not intended to advertise the products or provide any medical advice.

